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Dipyridamole-thallium (DTHAL) and sestamibi
(DMIBI) have both been shown to be useful tools
for detecting coronary artery disease.1-3 However,
the predictive value of DTHAL and DMIBI for
adverse cardiac events after vascular surgery remains
controversial. An early report by Boucher and col-
leagues noted a 50% cardiac event rate when the
reversible ischemia was demonstrated by means of
DTHAL and a 0% event rate with a negative result
of DTHAL.4 These observations were supported by
numerous subsequent studies,5-12 including the
report by Eagle and associates,5 who found that the
predictive value of DTHAL increased when it was
combined with clinical risk factors (diabetes mellitus,
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Purpose: This study assessed in a prospective, blinded fashion whether a reversible defect
on dipyridamole-thallium (DTHAL)/sestamibi (DMIBI) can predict adverse cardiac
events after elective vascular surgery in patients with one or more clinical risk factors.
Methods: Consecutive patients with one or more clinical risk factors underwent a preop-
erative blinded DTHAL/DMIBI. Patients with recent congestive heart failure (CHF) or
myocardial infarction (MI) or severe or unstable angina were excluded.
Results: Eighty patients (78% men; mean age, 65 years) completed the study. Diabetes
mellitus was the most frequent clinical risk factor (73%), followed by age older than 70
years (41%), angina (29%), Q wave on electrocardiogram (26%), history of CHF (7%),
and ventricular ectopy (3%). The results of DTHAL/DMIBI were normal in 36 patients
(45%); a reversible plus or minus fixed defect was demonstrated in 28 patients (36%),
and a fixed defect alone was demonstrated in 15 patients (19%). Nine adverse cardiac
events (11%) occurred, including three cases of CHF, and one case each of unstable angi-
na, Q wave MI, non-Q wave MI, and cardiac arrest (successfully resuscitated). Two car-
diac deaths occurred (2% overall mortality), one after a Q wave MI and one after CHF
and a non-Q wave MI. The cardiac event rate was 14% for reversible defect and 9.8%
without reversible defect (P = .71). The cardiac event rate was 12.5% (one of eight cases)
for two or more reversible defects, versus 11.1% (eight of 72 cases) for fewer than two
reversible defects (P = 1.0). The sensitivity rate of two or more areas of redistribution
was 11% (95% CI, 0.3%-48%), the specificity rate was 90%, and the positive and negative
predictive values were 12.5% and 89%, respectively.
Conclusion: Our study demonstrated no association between reversible defects on
DTHAL/DMIBI and adverse cardiac events in moderate-risk patients undergoing elec-
tive vascular surgery. (J Vasc Surg 2000;32:77-89.)
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Q wave on electrocardiogram, angina, history of
congestive heart failure [CHF], age older than 70
years, and ventricular ectopy requiring medical ther-
apy). Most of these studies, however, were limited
by their retrospective nature, the lack of use of con-
secutive patients, or the results of the DTHAL not
being blinded to all clinicians.
More recently, the usefulness of DTHAL and
DMIBI as preoperative screening tools has come into
question.13-18 In a prospective study of consecutive
patients undergoing vascular surgery, Mangano et al
found no association between reversible ischemia on
DTHAL and adverse cardiac events.16 All clinicians
were blinded to the DTHAL results.
We sought to determine whether the
DTHAL/DMIBI was predictive of adverse cardiac
events in moderate-risk patients undergoing elective
vascular surgery. Similar to the study by Mangano et
al, we enrolled consecutive patients, and the results
of the DTHAL/DMIBI were blinded to all clini-
cians. Our study differs in that we specifically
entered patients with one or more clinical risk fac-
tors, because these patients have been demonstrated,
at our institution as well as others, to be at a higher
risk for an adverse postoperative cardiac event.5,13,14
In addition, we wanted to determine whether two or
more reversible defects on DTHAL/DMIBI were
predictive of adverse cardiac events.
METHODS
Eligible patients underwent a preoperative
DTHAL (Veteran Affairs [VA] Greater Los Angeles
Health Services Medical Center) or DMIBI
(Harbor-UCLA Medical Center). The results of the
scan were blinded to all clinicians. Thus, there were
no alterations in medical, anesthetic, or surgical
management on the basis of these scans. Our proto-
col was approved by the Harbor-UCLA and VA
Medical Centers’ Human Subjects Committees, and
all patients gave informed consent.
Inclusion criteria. Consecutive patients sched-
uled for major vascular surgery at Harbor-UCLA
Medical Center and the West Los Angeles (LA) VA
Medical Center were prospectively examined by one
of the investigators for potential eligibility during
the 2-year study period, from June 1997 to June
1999. The study physician performed a routine his-
tory and examination and a review of medical
records. To be eligible for enrollment, the patient
had to have at least one clinical risk factor, as
described by Eagle and associates,5 and the planned
procedure had to be elective to allow time to sched-
ule a DTHAL/DMIBI. In addition, we limited the
procedures to infrarenal aortic procedures, infrain-
guinal reconstructions, and extra-anatomic bypass
grafting procedures. Carotid procedures were
excluded because of the shorter length of the oper-
ation, the lower level of hemodynamic stress, and
because adverse cardiac event rate in this procedure
is considered to be lower than that of infrainguinal
and aortic procedures. Suprarenal and thoracoab-
dominal procedures were excluded because these
operations present considerably higher hemodynam-
ic stress to the patient.
Rationale for inclusion criteria. Our two pre-
vious retrospective studies demonstrated a 0%
adverse cardiac event rate after elective vascular
surgery in patients with no clinical risk factors.13,14
Conversely, in patients with one or more clinical risk
factors, the cardiac event rate increased significantly,
to 6.7% (P < .05) at the West LA VA Medical Center
and to 7.5% (P < .05) at Harbor-UCLA Medical
Center.13-14 Eagle and colleagues similarly noted
only a 3.1% event rate in patients with no clinical risk
factors, a 15% event rate in patients with one or two
risk factors, and a 50% event rate in patients with
three or more risk factors.5 Thus, patients with no
clinical risk factors were considered to be at low car-
diac risk and proceeded to vascular surgery without
any preoperative cardiac evaluation.
Exclusion criteria. Some patients were excluded
from the study. Patients with severe cardiac symptoms
(NYHA class III angina, unstable angina, myocardial
infarction (MI) within the last 6 months, and decom-
pensated CHF were considered to be at high cardiac
risk13,14,16-19 and, thus, underwent the full preopera-
tive cardiac examination as directed by the cardiology
consultant. Other exclusion criteria included emergent
(within 24 hours) surgery (ie, ruptured aortic
aneurysm or acute limb ischemia) or urgent (within 72
hours) surgery (ie, progressive tissue loss or worsening
rest pain), nonatherosclerotic vascular disease, proce-
dures under strict local anesthesia, DTHAL/DMIBI
within the last 6 months, and contraindications to
receiving intravenous dipyridamole (allergy, severe pul-
monary disease). Although patients undergoing
endovascular aortic aneurysm repair were not specifi-
cally excluded, most of these patients were referred
from outside institutions because of their high opera-
tive risk and, as such, had already undergone extensive
cardiac testing. Patients who had undergone prior
coronary artery bypass grafting (CABG) were enrolled
only when the CABG procedure had been performed
more than 6 months earlier, when they had not under-
gone a post-CABG DTHAL/DMIBI, and when, after
the CABG, they still had a clinical risk factor.
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Rationale for use of dipyridamole-thallium
and sestamibi. Patients at the West LA VA Medical
Center underwent a 1-day DTHAL, whereas
patients at Harbor-UCLA Medical Center under-
went a 2-day DMIBI, because these were the estab-
lished nuclear cardiac imaging modalities at these
institutions. The accuracy of DMIBI as a means of
identifying coronary artery disease was established at
Harbor-UCLA Medical Center in previous stud-
ies.2,3 DMIBI differs from DTHAL in that tech-
netium-99m is used as the perfusion tracer, instead
of thallium-210. The shorter half-life of technetium-
99m permits injection of higher doses, providing
higher image count density. DMIBI undergoes min-
imal redistribution and has a radiation dosimetry
that is superior to thallium-201. Previous studies
have shown that DMIBI provides information
regarding coronary artery disease that is comparable
with DTHAL.
Technique of dipyridamole-thallium/sestamibi.
Patients were given an intravenous injection of 
dipyridamole (0.56 mg/kg) in 4 minutes under the
supervision of a physician. In the absence of systemic
effects on blood pressure or heart rate, 3.0 to 4.0 mCi
(depending on whether reinjection was necessary) of
thallium-201 was given 3 minutes after the 
dipyridamole infusion (at the VA). Single photon
emission computed tomographic (SPECT) images
were obtained 15 minutes and at 3 to 4 hours after
injection. At Harbor-UCLA Medical Center, 15 mCi
of technetium 99m-sestamibi was given intravenously
3 minutes after the completion of the dipyridamole
infusion. A rest study was performed the next day, with
reinjection of technetium-99m.
Perfusion defects were classified as fixed or
reversible and categorized by means of their loca-
tion and the number of areas involved. Reversible
defects were categorized as small, moderate, or
large. The results of the study were recorded by a
nuclear radiologist who was blinded to the clinical
history of the patient.
Perioperative management. Perioperative man-
agement did not deviate from the standard approach
at our institutions. Medical consultation was
obtained preoperatively for optimization. Medical
management was not altered because of the
DTHAL/DMIBI, because the clinicians were blind-
ed to the results. The addition of new medications
(eg, nitrates, beta blockers) both preoperatively and
postoperatively, was left to the discretion of the con-
sulting internist with the surgical team and was
based on the patient’s clinical history and the results
of the examination. The type of anesthetic used
(general, epidural, spinal) and the use of a pul-
monary artery catheter were likewise determined by
the attending anesthesiologist and were based on
clinical assessment. Cardiovascular medications, the
use of a pulmonary artery catheter, and the anes-
thetic type were recorded.
A study physician assessed the patient postopera-
tively on a daily basis until discharge.
Data were collected prospectively by the investi-
gator, who was blinded to the DTHAL/DMIBI
results. After surgery, the patients were monitored in
the intensive care unit for at least 24 hours postop-
eratively. Creatine phosphokinase (CPK) levels with
myocardial isoenzymes were obtained every 8 hours
on the first day and then every 12 hours for the next
4 days, or until discharge when the patient was sent
home before 4 days. A daily electrocardiogram was
obtained for the first 3 days. Additional serial CPK
levels with MB were obtained for episodes of tachy-
cardia, chest pain, hemodynamic instability, or
shortness of breath that were suspected to be of car-
diac origin.
Safety monitoring. An interim analysis was per-
formed after 50 patients were enrolled to ensure
patient safety. If this interim analysis demonstrated a
strong association between a reversible defect on
DTHAL/DMIBI and adverse cardiac events, the
study would be halted. In addition, when an adverse
postoperative cardiac event developed in a study
patient, the results of the DTHAL/DMIBI would
be unblinded at the clinicians’ request.
Definitions of adverse cardiac events. An
adverse outcome was noted by one of the investiga-
tors and was independently confirmed by two cardi-
ologists blinded to the patient’s DTHAL/DMIBI
results. In the event of a disagreement, a consensus
was used. An adverse cardiac event was defined as
one occurring within 30 days of surgery or during
the index hospital stay. Adverse postoperative cardiac
events were defined as Q wave and non-Q wave MI,
CHF, ventricular tachycardia, unstable angina, car-
diac arrest, and cardiac death. MI was defined as
meeting two of three criteria: (1) an elevation of the
serum creatinine kinase MB isoenzyme level to more
than 5%; (2) new Q wave on electrocardiogram or
persistent changes in the sinus tachycardia-T wave;
and (3) chest pain lasting longer than 30 minutes, or
evidence of acute infarction at autopsy. CHF was
defined as: (1) symptoms or signs of pulmonary con-
gestion (shortness of breath or rales); (2) symptoms
or signs of new left or right ventricular failure (car-
diomegaly, S3 heart sound, jugular venous disten-
tion, or peripheral edema); (3) abnormal chest radi-
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ography findings (vascular redistribution, interstitial,
or alveolar edema); and (4) a change in medication
involving at least diuretic treatment. Ventricular
tachycardia was defined as consecutive premature
ventricular contractions lasting more than 30 sec-
onds, more than 30 beats, and resulting in hypoten-
sion less than 90 mm Hg. Unstable angina was
defined as typical precordial chest pain consistent
with ischemia, lasting 30 minutes or longer, unre-
sponsive to nitroglycerin and rest, or a crescendo
pattern of angina occurring at a lower threshold or
higher frequency. Cardiac arrest and cardiac death
were defined as arrest or death from a dysrhythmia
or CHF caused by a cardiac complication.
Statistical analysis. Potential univariate corre-
lates of adverse cardiac outcome were identified by
using the chi-square or Fisher exact tests when
appropriate. Continuous variables were compared
with the use of the Wilcoxon rank-sum test. Other
factors compared included sex, history of smoking,
history of CABG, Eagle risk factors, type of vascular
procedure (aortic versus nonaortic), findings on
DTHAL/DMIBI (normal, fixed or reversible
defect), the presence of two or more reversible
defects on DTHAL/DMIBI, the number of
reversible defects, serum creatinine levels, use of
perioperative nitrates and/or beta blockers, type of
anesthetic (general, spinal, epidural), and the intra-
operative use of a pulmonary artery catheter. A P
value of less than .05 was considered statistically sig-
nificant. No adjustment was made for multiple com-
parisons. All statistical comparisons were performed
with the SAS statistical software package (SAS
Institute, Cary, NC).
RESULTS
Ninety-one patients were enrolled in the study.
Of these, 11 patients were excluded before the com-
pletion of the DTHAL/DMIBI, leaving 80 patients
(50 at Harbor-UCLA Medical Center and 30 at the
West LA VA Medical Center). In four cases, a new
cardiac event developed in the patient (CHF in two
patients, and one patient each with unstable angina
and non-Q wave MI) after they signed the consent
but before the DTHAL/DMIBI was performed. In
four cases, patients either failed to keep the appoint-
ment for the DTHAL/DMIBI or decided after
signing the consent that they no longer wanted to
participate in the study. In two cases, the patient was
deemed to be at high cardiac risk at the time of pre-
operative evaluation by internal medicine (one
patient) or by anesthesiology (one patient), because
the patients’ symptoms of angina were more severe
than originally appreciated. Wheezing developed in
one patient after injection of dipyridamole, and the
study was, therefore, cancelled.
Results of dipyridamole-thallium/sestamibi.
Chest tightness developed in one patient during
DTHAL, but the study was successfully completed.
No other patient had a complication from DTHAL
or DMIBI. The results of DTHAL/DMIBI were
normal in 36 patients (45%) and demonstrated a
reversible defect plus or minus fixed defect in 29
patients (36%) and a fixed defect alone in 15 patients
(19%). Of the 29 patients with a reversible defect, 21
patients had one area of reversible defect, seven
patients had two areas of reversible defects, and one
patient had three areas of reversible defects. 
The mean age of the 80 patients was 65 years.
Seventy-eight percent of the patients were men.
Cardiovascular risk factors are listed in Table I. The
mean number of clinical risk factors per patient was
1.8 (range, 1-4). There were 65 infrainguinal proce-
dures (femoropopliteal, tibial, or pedal), seven pro-
cedures for aortoiliac occlusive disease, six infrarenal
aortic aneurysms, one iliofemoral bypass grafting
procedure, and one axillofemoral bypass grafting
procedure. Sixty patients (75%) underwent general
anesthesia, 18 patients (22%) underwent epidural
anesthesia, and five patients (6%) underwent spinal
anesthesia (some patients had both general and
epidural anesthesia).
There were nine (11.2%) adverse postoperative
cardiac events, including three in patients with CHF
and one each in patients with unstable angina, Q
wave MI, non-Q wave MI, or cardiac arrest (suc-
cessfully resuscitated). Two additional patients died
of a cardiac etiology (overall cardiac mortality rate,
2.5%). CHF and a non-Q wave MI developed in one
patient. The other patient had a Q wave MI. 
Primary analysis. The adverse cardiac event rate
was 9.8% for patients without a reversible defect on
DTHAL/DMIBI and 13.8% for patients with a
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Table I. Cardiovascular risk factors (n = 80) 
Risk factor Number of patients (%)
Diabetes mellitus 59 (73)
History of smoking 62 (67)
Age older than 70 years 33 (41)
Currently smoking 26 (33)
Q wave on ECG 21 (26)
Angina 23 (29)
History of CHF 7 (9)
Ventricular ectopy 2 (3)
ECG, Electrocardiogram; CHF, congestive heart failure.
reversible defect (P = .75; odds ratio [OR], 1.5; 95%
CI, 0.4-5.9). The event rate was 8.3% for patients
with normal DTHAL/DMIBI results and 13.3% for
those with a fixed defect alone (P = .7). There was
also no difference in event rate between patients
with normal scan results (8.3%) and those with
abnormal results (fixed or reversible) on the
DTHAL/DMIBI (13.6%; P = .5; OR, 1.7; 95% CI,
0.4-7.5). The cardiac event rate was 14.2% (three of
21) for patients with one reversible defect, 14.3%
(one of seven) for patients with two reversible
defects, and 0% for patients with three reversible
defects (one patient; P = 0.5). The cardiac event rate
was 12.5% (one of eight) for patients with two or
more reversible defects, versus 11.1% (eight of 72)
for fewer than two reversible defects (P = 1.0; OR,
1.1; 95% CI, 0.1-10.5; Tables II and III). Both cases
of cardiac death occurred in patients with one area
of reversible defect. Thus, the cardiac death rate was
0% for patients with no reversible defects, versus
6.8% for patients with a reversible defect (P = .13).
The cardiac death rate was 2.7% for patients with
one or no reversible defects, versus 0% for patients
with two or more reversible defects (P = 1.0). The
sensitivity rate, specificity rate, and positive and neg-
ative predictive values (with 95% CIs) for a normal
study and for one and two reversible defects are list-
ed in Table IV. Of the three patients with complete-
ly normal DTHAL/DMIBI results, two underwent
infrainguinal reconstruction, and one underwent
aortic surgery. There was no correlation between
intraoperative adverse events (hypotension, bleed-
ing) and the subsequent development of adverse car-
diac events.
Secondary analysis. We also performed analysis
for adverse cardiac events, excluding CHF (n = 6) as
an adverse event (because some may argue that CHF
is not ischemic event). For this analysis, there was no
difference in adverse events between patients with
normal DTHAL/DMIBI results (5.5%) and abnor-
mal (fixed or reversible) scan results (9.1%; P = .6;
OR, 0.6; 95% CI, 0.1-3.4), and there was no differ-
ence in adverse events between patients with
reversible ischemia (10.3%) and patients with no
reversible ischemia (normal or fixed; 5.9%; P = .7;
OR, 0.5; 95% CI, 0.1-2.9). There was no difference
in the cardiac event rate between patients with one
or no reversible defects on DTHAL/DMIBI (8.3%)
and patients with two or more reversible defects (0%;
P = 1.0).
The adverse cardiac event rate was significantly
higher for aortic procedures (four of 13, 31%) than
for infrainguinal/extra-anatomic procedures (five of
67, 7.5%; P = .03). Because the event rate was high-
er in the aortic procedure group, we analyzed the
predictive value of DTHAL/DMIBI in this sub-
group. The cardiac event rate was 33% (three of
nine) for patients with reversible ischemia and 25%
(one of four) for patients without reversible ischemia
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Table II. Dipyridamole-thallium/sestamibi results in patients with adverse cardiac events
Event DTHAL results DMIBI results
1. Unstable angina Normal
2. CHF Moderate inferior reversible defect
Small anteroapical reversible defect
Small inferior fixed defect
3. Q wave MI Small anterospetal fixed defect
Moderate apical fixed defect
4. CHF Moderate apical fixed defect
Large inferior/posterior fixed defect
5. Non-Q wave MI, CHF, death Moderate inferior reversible defect
6. Cardiac arrest Small to moderate inferior reversible defect
7. Non-Q wave MI Normal
8. CHF Normal
9. Q wave MI, death Small inferior reversible defect
DTHAL, Dipyridamole-thallium; DMIBI, sestamibi; CHF, congestive heart failure; MI, myocardial infarction.
Table III. Adverse cardiac event rate with dipyri-
damole-thallium/sestamibi results
DTHAL/DMIBI result Cardiac event rate
Normal 3/36 (8.3%)
Normal or fixed 5/51 (9.8%)
Fixed alone 2/15 (13.3%)
Reversible defect ± fixed 4/29 (13.8%)
≥ 2 reversible defects 1/8 (12.5%)
≥ 3 reversible defects 0.1 (0%)
DTHAL, Dipyridamole-thallium; DMIBI, sestamibi.
(P = 1.0; OR, 1.5; 95% CI, 0.1-21).
No statistically significant associations was
revealed by means of the univariate analysis of other
clinical factors (Table V). Because all patients had at
least one clinical risk factor, the univariate analysis of
individual clinical risk factors is not reported. The
mean number of clinical risk factors per patient in
patients with an adverse cardiac event was 1.4, ver-
sus 1.9 for patients without an event (P = .18). The
mean operative time for patients with a cardiac event
was 314 minutes versus 311 minutes for patients
without a cardiac event (P = .9).
DISCUSSION
This study demonstrated no association between
a reversible defect on DTHAL/DMIBI and adverse
postoperative cardiac events in moderate-risk
patients undergoing elective major vascular surgery.
A reversible defect had a sensitivity rate of 44% and
a positive predictive value of only 14% for an adverse
cardiac event. Two or more reversible defects had a
sensitivity rate of only 11% (95% CI, 0.3-48), a
specificity rate of 90%, a positive predictive value of
12.5%, and a negative predictive value of 89%. Of
the nine adverse cardiac events, 56% occurred in
patients with normal results on DTHAL/DMIBI or
with a fixed defect. In fact, the adverse cardiac event
rate was 8.3% in patients with normal
DTHAL/DMIBI scan results, which was not signif-
icantly different from the event rate in patients with
a fixed defect (13.3%) or in patients with a reversible
defect (13.8%). There was also no difference in event
rates between patients with normal scan results
(8.3%) and patients with abnormal (fixed or
reversible) scan results (13.6%; P = .5). The OR was
1.7 (95% CI, 0.4-7.5). Whether this OR is clinically
significant is debatable. Although some authors have
noted a correlation between a fixed defect and an
adverse cardiac event, most cardiologists would not
recommend canceling surgery, coronary arteriogra-
phy, or additional cardiac testing because of a fixed
defect. When excluding CHF as an adverse event,
there was still no relationship between adverse
events and abnormal scan results or reversible
ischemia. The overall adverse cardiac event rate of
11.2% is comparable with what we and others have
previously observed in patients with one or more
clinical risk factors. However, the adverse cardiac
event rate was significantly higher in patients who
underwent aortic surgery (31%) than in patients
undergoing nonaortic surgery (7.5%; P = .03). The
analysis of the aortic subgroup also showed no cor-
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Table IV. Predictive value of dipyridamole-thallium/sestamibi (with 95% CIs)
DTHAL/DMIBI result Sensitivity Specificity (+) Predictive value (–) Predictive value P value
Normal 33% (7% to 70%) 53% (41% to 65%) 8% (2% to 22%) 86% (73% to 95%) .5
≥1 reversible defect 44% (14% to 79%) 65% (53% to 76%) 14% (4% to 32%) 90% (79% to 97%) .72
≥2 reversible defects 11% (0.3% to 48%) 90% (81% to 96%) 12.5% (0.3% to 53%) 89% (79% to 95%) 1.0
DTHAL, Dipyridamole-thallium; DMIBI, sestamibi.
Table V. Univariate analysis for adverse cardiac event
Cardiac event No cardiac event
Factor (n = 9) (n = 71) P value
Male sex 7 (78%) 55 (77%) 1.0
History of smoking 7 (78%) 46 (66%) .7
Current smoker 4 (44%) 22 (31%) .5
Prior coronary artery bypass graft 2 (22%) 8 (11%) .4
Harbor-UCLA patient 5 (56%) 45 (63%) .7
West LA VA patient 4 (44%) 26 (37%) .7
Aortic procedure 4 (44%) 9 (13%) .03
Perioperative nitrate 1 (11%) 8 (11%) 1.0
Perioperative beta-blocker 3 (33%) 26 (37%) 1.0
General anesthesia 7 (78%) 54 (76%) 1.0
Spinal anesthesia 0 5 (8%) 1.0
Epidural anesthesia 3 (33%) 15 (21%) .4
Pulmonary artery catheter 2 (22%) 16 (22%) 1.0
Intraoperative nitrate 3 (33%) 14 (20%) .4
relation between a reversible defect on
DTHAL/DMIBI (P = 1.0) and an adverse cardiac
event. Although there is no evidence in the present
study of a correlation between a reversible defect
and a cardiac event in the aortic subgroup, the small
number of aortic surgery patients enrolled (n = 13)
and the wide 95% CI for the OR (0.1-21) raise the
possibility of a type-II error.
The lack of predictive value of DTHAL/DMIBI
in the present study contradicts earlier reports
(Table VI). However, in most instances, these
reports were either retrospective, did not involve
consecutive patients, or the results of the DTHAL
were not blinded.4-11 In a retrospective review of
254 vascular patients referred to a nuclear cardiolo-
gy laboratory, Eagle and colleagues5 noted that
DTHAL results were best used when combined with
the clinical risk factors. In patients with one or two
clinical risk factors, Eagle et al noted a 29.6% cardiac
event rate in patients with a reversible defect on
DTHAL, versus only a 3.2% event rate in patients
with no reversible defect. Because the DTHAL
results were not blinded, 44 patients had the surgery
cancelled or postponed because of abnormal
DTHAL results and were not included in the analy-
sis.5 In a prospective study of 116 consecutive
patients undergoing aortic surgery, Cutler and
Leppo6 noted that all postoperative MIs and deaths
occurred in the 54 patients with a reversible defect
on DTHAL. However, because the results of the
DTHAL were not blinded, 20 patients with abnor-
mal DTHAL results underwent preoperative cardiac
catheterization. One patient sustained a cerebrovas-
cular accident after catheterization. Another patient
died of a ruptured abdominal aortic aneurysm while
awaiting coronary revascularization. Six patients
underwent CABG. One of these patients died 3 days
later of hemorrhagic pancreatitis.6 Vanzetto et al12
prospectively studied 134 consecutive high-risk
patients (those with two or more clinical risk factors)
undergoing aortic surgery. The DTHAL results
were blinded. The major cardiac event rate (MI and
cardiac death) was 23% in patients with a reversible
defect and 1% in patients without a reversible defect
(P < .01), and the overall cardiac event rate (includ-
ing CHF, unstable angina, and ventricular arrhyth-
mias) was 50% in patients with a reversible defect
and 7% in patients without a reversible defect (P <
.0001).12 The percentage of patients with reversible
ischemia (36%) in the present study is identical to
that noted by Vanzetto et al.12
Our findings are supported by several recent
studies (Table VII). In a prospective study of 60
consecutive patients, Mangano and colleagues16
found no association between DTHAL redistribu-
tion and adverse cardiac outcome. Similar to the 
current study, they noted that 58% of severe periop-
erative cardiac ischemic episodes occurred in
patients without redistribution defects. The sensitiv-
ity of DTHAL for adverse cardiac outcome was only
46%, and the positive predictive value was only
27%.16 Because the DTHAL results were blinded,
vascular surgery was neither delayed nor modified,
preoperative cardiac catheterization was not
obtained, and medical and anesthetic care were not
changed by the DTHAL results.16 In two retrospec-
tive studies, de Virgilio and associates found that
DTHAL and DMIBI redistribution were not pre-
dictive of adverse cardiac events in patients without
severe cardiac symptoms (recent MI, unstable angi-
na, decompensated CHF).13-14 The positive predic-
tive values of DTHAL and DMIBI for adverse car-
diac events were 6% and 10%, respectively.13-14 In a
prospective study of 457 consecutive patients under-
going abdominal aortic surgery, Baron et al also
found that DTHAL results did not accurately pre-
dict adverse cardiac outcomes.15 The best correlates
of cardiac complications were definite clinical evi-
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Table VI. Selected studies demonstrating association between dipyridamole-thallium redistribution and
adverse cardiac events
DTHAL Consecutive (+) Predictive (–) Predictive
Author (y) blinded Prospective patients Sensitivity Specificity value value P value
Boucher et al (1985)2 No No No 100% 80% 50% 100% .0001
Cutler, Leppo (1987)4 No Yes Yes (aortic) 100% 69% 23% 100% .001
Eagle et al (1989)3 No No Yes* 83% 66% 30% 96% < .0001
Vanzetto et al (1996)9 Yes Yes Yes† (aortic) 80% 77% 50% 93% < .0001
*Study reviewed consecutive patients referred to cardiology for DTHAL, not consecutive patients scheduled for surgery.
†Study enrolled consecutive patients with two or more clinical risk factors.
DTHAL, Dipyridamole-thallium.
dence of coronary artery disease and an age older
than 65 years.15 Stratmann et al noted a 3% cardiac
event rate in 87 patients with normal DMIBI results
and a 5% event rate in the 110 patients with abnor-
mal DMIBI results (P = not significant).17 Of the
110 patients with abnormal DMIBI results, 53 had
reversible defects, and the cardiac event rate in this
subgroup of patients was only 6% (P = not signifi-
cant versus normal or fixed defect).
Similar to the study of Mangano et al, the cur-
rent study was prospective, the DTHAL/DMIBI
results were blinded, and consecutive patients were
enrolled. However, the present study differed in sev-
eral respects. First, to try to optimize the results of
the DTHAL/DMIBI, we only included patients
with clinical (Eagle) risk factors, because these
patients are at moderately increased risk for an
adverse cardiac event. Second, we enrolled patients
at two institutions to get a broader patient popula-
tion with varied cardiac risk factors. On the basis of
our previous studies, we noted that diabetes mellitus
was more prevalent in patients undergoing vascular
surgery at Harbor-UCLA Medical Center (50%)
than at the West LA VA Medical Center (33%),
whereas more patients at the West LA VA Medical
Center were older than 70 years (32% vs 14%), had
a Q wave on EKG (31% vs 14%), and had a history
of CHF (12% vs 6%).13,14 Third, we used SPECT
imaging for the DTHAL/DMIBI, which is thought
to increase the sensitivity for reversible defects.20 We
used DTHAL at Harbor-UCLA and DMIBI at the
West LA VA Medical Center, because these were the
established nuclear cardiac imaging modalities at
these respective institutions. Although this is a
potential weakness of our study, the similarity of
these two imaging techniques for detecting coro-
nary artery disease has been previously established.
Finally, we analyzed our results both by means of the
presence of a reversible defect and by using the num-
ber of reversible defects. Despite these differences,
the results from the present study are similar to
those of Mangano et al.
The discrepancy between the present study and
earlier studies that show a favorable predictive value
for DTHAL/DMIBI may be explained as follows.
In earlier studies showing DTHAL benefits 
(other than the study by Vanzetto et al), the
DTHAL/DMIBI results were not blinded. As such,
medical, surgical, and anesthetic treatment may have
been altered in patients with reversible defects. In
some instances, surgery was cancelled, or the surgery
was postponed to obtain coronary arteriography. In
several earlier studies, the data were not collected
prospectively, and therefore, some adverse cardiac
events may have been missed. Patients enrolled in
most earlier studies were not consecutive patients,
but rather select patients who were referred for
nuclear cardiac imaging. Consequently, a selection
bias may have occurred. Most prior studies did not
specifically enroll moderate-risk patients, but rather
included patients without a clinical risk factor. An
exception was the study by Vanzetto et al, which
enrolled patients with at least two cardiac risk factors
similar to the risk factors described by Eagle and col-
leagues. In fact, in their study, patients had a mean
of 4.1 risk factors, which may explain the high
reported cardiac event rate (22%).12 Another differ-
ence is that most prior studies used planar imaging,
whereas SPECT imaging was used in the present
study. However, the inclusion of only moderate-risk
patients and the use of SPECT in the current study
should have increased the positive predictive value
and the sensitivity of DTHAL, which was not the
case. The type of vascular operation studied differs
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Table VII. Studies demonstrating no association between dipyridamole-thallium/sestamibi redistribution
and adverse cardiac events
DTHAL Consecutive (+) Predictive (–) Predictive
Author (y) blinded Prospective patients Sensitivity Specificity value value P value
Mangano et al (1991)12 Yes Yes Yes 46% 66% 27% 82% .43
Seeger et al (1994)14 No Yes Yes (aortic) 40% 50% 11% 84% .47
Baron et al (1994)11 No Yes Yes (aortic) 36% 65% 19% 81% .9
Stratmann et al (1995)13 No Yes Yes* 33% 73% 6% 96% .7
de Virgilio et al (1996)10 No No No 25% 80% 10% 92% 1.0
de Virgilio et al (1996)11 No No No 40% 43% 6% 89% .64
Present study Yes Yes Yes† 44% 65% 14% 90% .72
*Enrolled consecutive patients with either stable angina or one or more risk factors for coronary artery disease.
†Enrolled consecutive patients with one or more Eagle risk factors, aortic or infrainguinal surgery.
DTHAL, Dipyridamole-thallium.
between series. Many earlier studies have focused
solely on aortic cases, whereas the current study
included both aortic and infrainguinal procedures.
We believed this was justified, because Krupski et
al21 showed that the adverse cardiac event rates for
infrainguinal procedures are at least as high as those
for aortic procedures. As noted in our results, how-
ever, we detected a statistically higher adverse car-
diac event rate in the patients undergoing aortic pro-
cedures. Although no predictive value of
DTHAL/DMIBI was detected by means of our
analysis in the small subgroup of aortic patients, the
OR was 1.5, with a 95% CI of 0.1 to 21. Another
difference between studies involves the definition of
adverse end points. In the present study, we used
CHF as one of the adverse end points, as has been
done in numerous other studies.15,16,18 Other
authors have argued that CHF may occur because of
iatrogenic fluid overload and have thus not included
CHF as an end point.5-7 Nevertheless, in the present
study, there was still no correlation between
reversible ischemia on DTHAL/DMIBI and adverse
cardiac events when CHF was excluded. The lack of
predictive value of DTHAL/DMIBI may be
explained by the unexpected physiologic changes
during the perioperative period (eg, sudden hypox-
ia, excessive blood loss) that are not necessarily pre-
dictable by means of preoperative criteria.
Over and above the question of whether
DTHAL/DMIBI is a sensitive test for predicting
adverse cardiac events, one must consider the risks of
extended cardiac evaluation and the cost. de Virgilio
et al14 reported that obtaining a DTHAL delayed
time to surgery from 12 days to 18 days (P = .0003)
without altering the cardiac event rate. In patients
undergoing CABG before peripheral vascular
surgery, Hertzer et al noted a mortality rate after
CABG of 5.3%, and in the subset of patients with
aortic aneurysms, 2.9% sustained a rupture of the
aortic aneurysm after CABG and died.22
Massie et al noted that the risks of extended car-
diac evaluation and treatment did not produce any
improvement in either the perioperative or long-
term survival rate.23 This latter study is particularly
noteworthy because the authors previously advocat-
ed the use of DTHAL. Taylor et al noted no opera-
tive deaths and no fatal MIs in 285 consecutive elec-
tive major vascular procedures performed over 1
year.19 In their study, only patients with severe car-
diac symptoms (unstable angina, severe CHF,
uncontrolled arrhythmia), who represented only
5.8% of the study group, underwent extended car-
diac testing, which consisted of proceeding directly
to coronary angiography. We have previously advo-
cated a similar approach.13,14 Finally, the cost of
DTHAL is an important issue. Bry et al24 estimated
an average cost of $3092 per patient for DTHAL
screening and cardiac intervention, and a cost of
$181,000 per MI prevented. They further noted
that most postoperative MIs were clinically insignif-
icant.
Potential weaknesses of the present study should
be noted. The number of patients enrolled was fewer
(80 patients) than the study by Vanzetto et al (134
patients). Nevertheless, the present study is the sec-
ond largest prospective blinded study in moderate-
risk patients. For one or more areas of reversible
ischemia, the OR for an adverse cardiac event was 1.5,
with a 95% CI ranging from 0.1 to 5.9. For two or
more areas of ischemia, the OR was 1.1 (95% CI, 0.1-
10.5). This finding is important, because most cardi-
ologists would only recommend coronary angiogra-
phy for patients with two or more areas of reversible
ischemia. The low sensitivity rate (11%) of two or
more reversible defects for adverse cardiac events in
the present study (with a 95% CI of 0.3 to 48) makes
it highly unlikely that adding more patients to the
study would increase the sensitivity rate of the test to
more than 50%. Another study weakness is that we
did not control for the use of perioperative medica-
tions or intraoperative monitoring with pulmonary
artery catheters, although these variables did not
affect the cardiac event rate on univariate analysis.
Finally, 11 patients were excluded from the study
before obtaining the DTHAL/DMIBI; four of these
patients sustained an adverse cardiac event before
obtaining the scan. It is unknown whether the addi-
tion of these patients would have altered our results.
In summary, our findings support other recent
studies that demonstrate no correlation between a
reversible defect on DTHAL/DMIBI and an adverse
cardiac event after elective vascular surgery. Given the
added time and expense incurred in obtaining a pre-
operative DTHAL/DMIBI and its lack of predictive
value, we would recommend reassessing its use as a
tool for preoperative cardiac assessment before elec-
tive major vascular surgery. Studies are now under-
way that will help us to determine whether preoper-
ative coronary revascularization will lower periopera-
tive cardiac morbidity and mortality.
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DISCUSSION
Dr William C. Krupski (Denver, Colo). I would like to
thank the Program Committee for asking me to discuss Dr
de Virgilio’s presentation this morning, and I compliment
him on a wonderful job. Moreover, he forwarded the
manuscript to me well in advance of this meeting, so I had
plenty of time to study it. The manuscript is particularly
well written, and I commend it to you all when it appears
in print, as I am sure it will.
Dr de Virgilio has followed an important principle of
clinical research. He and his colleagues at Harbor-UCLA
developed a hypothesis regarding the utility of preoperative
dipyridamole-thallium/sestamibi scans to assess cardiac risk
before vascular surgery based on two retrospective studies
that have already appeared in the literature (De Virgilio et
al. Ann Vasc Surg 1996;10;325-9 and de Virgilio et al. J
Vasc Surg 1998;32:275-80). However, as we know, retro-
spective studies—like post hoc analyses of prospective tri-
als—are hypothesis seeking, not hypothesis proving. Today,
he has presented the “second-best” way to prove a hypoth-
esis; namely, a prospective, blinded study of consecutive
patients. The only better method of obtaining such proof
is the large, (often multicenter) randomized prospective
trial, showing the benefit (or lack thereof) of an interven-
tion in groups of matched patients. In brief, the Harbor-
UCLA group has shown that DTS was essentially ineffec-
tive in accurately predicting postoperative adverse cardiac
events. A “negative” study was somewhat helpful, but the
negative predictive value was only 89%, so as many as one
in 10 of our patients with a “normal” scan may experience
an adverse postoperative cardiac event. Even worse, the
positive predictive value was only 12.5%, so a positive scan
is next to useless for identification of patients at most risk
for untoward outcomes. Think of the money and effort
wasted if all patients with positive scans had gone on to
have additional tests, such as cardiac catheterizations!
I have very few criticisms of Dr de Virgilio’s study.
Obvious concerns arise about the potential for Type II sta-
tistical errors because of the relatively small number of
patients. It is not clearly stated whether all treating physi-
cians (including anesthesiologists) were blinded to scan
results. A uniform anesthetic technique, perhaps including
the routine use of perioperative beta blockers, might have
made this a “cleaner” study. Routine ECGs and enzymes
were obtained for only the first three postoperative days,
whereas we have previously shown that many MIs occur on
days 5 through 7 (Krupski et al. J Vasc Surg 1992;15:354-
65). Finally, some might denounce excluding the highest
risk patients and combining results of two different tests
performed by different individuals at two different institu-
tions. Personally, I think these are all minor weaknesses.
Enthusiasm for DTS peaked in the last decade, when
groups (mostly from Boston schools) showed favorable
results of preoperative stress scans. However, there is an
informative table in the manuscript, indicating that no fewer
than seven published studies from the 1990s showed no
predictive value of redistribution on stress scans. It is always
delightful to discuss a paper that confirms one’s own biases,
and I was fortunate to participate in one of the earliest
doubting reports cited by Dr de Virgilio when I had the
pleasure of working at the San Francisco VAMC. Like
today’s presentation, in that study, treating physicians were
blinded to scan results, and over half of postoperative
ischemic cardiac events occurred in patients without redis-
tribution defects (Mangano et al. Circulation 1991;84:493-
502). Since our publication, the number of reports and
patients showing that scans are of little benefit has increased
dramatically, including one trial in Paris involving 457
patients. (Baron et al. N Engl J Med 1994;330:663-9).
Despite all this overwhelming evidence—including
today’s results—that DTS is not what it was initially
cracked up to be, referring physicians, consulting cardiol-
ogists, anesthesiologists, and others continue to demand
these tests. Dr de Virgilio, how do we reverse this behav-
ior? How do we convince our colleagues that stress scan-
ning is neither accurate nor cost-effective? Do you plan to
perform a randomized controlled trial comparing the out-
comes of patients having scans with those managed with-
out them, or are your present data sufficiently persuasive?
Finally, what is your current practice with respect to pre-
operative cardiac evaluation; are there still patients who
warrant scans or do you recommend cardiac angiography
as a primary investigation in the highest risk group?
I enjoyed this presentation very much, and I hope
the excellent manuscript makes as important an impact
as it deserves.
Dr Christian de Virgilio. First of all, I wanted to thank
Dr Krupski for his comments, and I wanted to say that he
and the perioperative ischemia group have been a source
of inspiration for me as they laid the foundation for this
work back in 1990.
The first question was how do we reverse the behavior
of our colleagues in cardiology. That was sort of my initial
intent because despite your study and the study of others,
the cardiologists still insisted on obtaining a DTHAL or
DMIBI prior to approval of the patient going to the OR.
The kicker that was thrown in by cardiology was that
Eagle and colleagues indicated that the DTHAL was use-
ful in patients with one or more Eagle risk factors.
So in the design of the study we added the element of
including only patients who we have previously demon-
strated to be at higher cardiac risk. That is, in our own
institution patients without an Eagle risk factor had essen-
tially a 0% adverse cardiac event rate, whereas those with
one or more had an increased cardiac event rate.
The second thing was that our study used SPECT
scanning instead of planar imaging, and SPECT has been
reported to have a much greater sensitivity for picking up
areas of ischemia. So by including patients with only one
or more risk factors and including SPECT scanning as the
basis of our study, we were hoping to improve both the
sensitivity and the positive predictive value of the test, nei-
ther of which proved true in this study.
So to answer your question, I think it is a matter of
going to cardiologists at your individual institution and
educating them with regard to what is out there in the lit-
erature. We have done that ourselves at Harbor UCLA in
the form of multidisciplinary conferences. We now have a
better ability to convince them not to obtain this test.
As far as performing a randomized controlled trial, I
personally feel convinced at this point that the DTHAL
and the DMIBI really do not have any value as far as pre-
dicting adverse events. There is literature, particularly the
group of Stratmann and colleagues, that demonstrated
that the dipyridamole Sestamibi is useful in predicting who
is going to have a cardiac event long term. So there may
be some utility in that respect.
The thing to point out is that even though our study
was a small number, when one looked statistically at the
95% CI for the sensitivity of two or more areas of
ischemia, that 95% CI interval went from 0.3% to only
48%. So we felt fairly confident that at best, two or more
areas of ischemia were a coin toss as far as the sensitivity.
We await your future studies, that is, the CARP trial,
as far as looking at whether preoperative cardiac revascu-
larization will, in fact, benefit these patients. As far as my
own current practice, we basically have adopted the policy
of the group in Oregon in which only patients who have
severe obvious cardiac symptoms undergo preoperative
evaluation, and in those instances basically I would rec-
ommend going directly to catheterization.
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In other patients who do not have any overt symp-
toms, my feeling is the event rate is too low and that
putting patients through three interventions, that is, a car-
diac catheterization, a PTCA, and/or a coronary bypass
followed by a vascular surgery, is going to be a greater risk
than simply proceeding with the vascular operation.
Thank you again, and I want to thank my colleagues
as well as the American Heart Association, who sponsored
this study.
Dr Kraiss. Very nice study, and I applaud you on going
to all the work to actually conduct a prospective study.
However, if you look at your raw numbers, your patients
who had some abnormality on DTHAL had almost a 60%
to 100% increase in cardiac events compared with the
patients who had normal scans in a larger study that is like-
ly to become statistically significant.
I would like to propose to you another use of the scan:
that is using the scan to help decide whether to do an oth-
erwise completely elective operation and to counsel the
patient. We take a patient with a 5-cm aneurysm, for
instance, and we quote the patient a less than 5% morbid-
ity and mortality based on many other studies. On the
other hand, your patients who had a defect on deep
DTHAL had between a 10% and 15% incidence of cardiac
event rate.
So I would propose to you that the DTHAL might
actually help you counsel the patient, and in a patient who
has a 5-cm aneurysm who has a fixed or reversible defect
on dipyridamole-thallium scan, that patient might be the
one for whom you say we need to wait. We may let this
aneurysm grow because the risk-benefit analysis of doing
a completely elective operation does not favor interven-
tion at this point. I think the same thing would apply to
patients who are being considered for elective operations
for claudication.
So I think there is some utility in this test. Even if you
decide not to aggressively pursue coronary intervention to
make the patient a better candidate for surgery, I think it
can help you in counseling the patient about whether or
not to even do the surgery.
Dr de Virgilio. I appreciate your comments, and I
would agree with you if we had found that the negative
predictive value of our test was worthwhile, but as I point-
ed out in our data, five of the nine adverse events occurred
in patients with a fixed defect or a normal defect. The neg-
ative predictive value was 89%, which means that basically,
our cardiac event rate in patients without redistribution
was 11%.
So I really do not know what to tell a patient because
even with a normal scan I do not feel reassured; in fact, as
a case in point, last week we had a patient with a renal
artery reconstruction. The patient himself had read about
the DTHAL and insisted that one be done. It was normal,
and then intraoperatively, the patient dropped his ST seg-
ments and had a positive troponin.
So I agree with you that in theory that would be good,
but the study just does not bear it out as far as the nega-
tive predictive value.
Dr Dalman. That was a nicely designed study. It was
well presented. I just do not believe that the data as
described support the conclusion that preoperative cardiac
“stress” testing should be abandoned. That conclusion
seems a little premature based on this presentation.
You combined different cardiac risks in your relatively
modest series (leg bypass and aortic aneurysm patients).
Bill Krupski has previously shown us (before this meeting)
that the leg bypass patient is clearly at greater risk for peri-
operative cardiac events that the AAA patient. So in mix-
ing these patients together you may have obscured the
value of testing for the truly “high-risk” patient. In addi-
tion, you used two different testing modalities at two dif-
ferent medical centers to reach your conclusions about the
“at risk” vascular patient. Several potential sources of error
are inherent in mixing such testing procedures and venues.
In extrapolating these data for our own practice, I also
note that the mean age of your patients (65 years) is sig-
nificantly younger than ours for any type of arterial recon-
structive procedure.
So in our particular case, where we have one colleague
in nuclear medicine with an interest in this area reviews all
of our studies, I believe our experience supports a differ-
ent conclusion. That is, we find stress testing provides use-
ful information regarding surgical decision making in our
high-risk patient population. We believe that despite the
results of this well-designed and carefully analyzed study,
it remains to be proven whether this type of preoperative
testing should “abandoned” at the current time.
Dr de Virgilio. I thank you for your comments. My
response to that would be the following: as Dr Krupski has
looked at in the past, patients who undergo infrainguinal
reconstruction have at least as high a perioperative cardiac
event rate as do patients with aortic surgery, and for that
reason we included both of them. We did not include
carotid patients because there is evidence in the literature
that they may have a lower event rate.
As far as the mixing of the patients, I recognize that that
is certainly a weakness of the study. However, our institu-
tion at Harbor UCLA was one of the early participants in
the cardiolite study that established our center as a center of
excellence for the use of the dipyridamole Sestamibi.
So I understand that there are some reservations; nev-
ertheless, in our patients and in our population, this test
has not been shown to benefit.
I would further add that ours is not the first study, but
one of several studies now including the study by
Mangano et al and the study by Baron and colleagues in
the New England Journal of Medicine that included 457
patients who underwent aortic surgery in which the
dipyridamole-thallium had no predictive value.
Dr Mitchell. I congratulate you on your presentation
and your persistence in trying to educate us about which
patients need a cardiac evaluation. One of the acknowl-
edged problems with these perfusion scans is if you have
patients who have homogenous malperfusion, and the
lesions that can be frequently missed are left proximal, left
main disease, and diffuse three-vessel disease.
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So my question is, first, if in your reporting they looked
at the ejection fraction before and after administration of
the drug because some scanners can actually show that if
you get global hypocontractility that in spite of fairly dif-
fuse perfusion suggests that there is diffuse disease.
Then second, of the patients with normal scans who had
cardiac events, how many of those had left main disease?
Those are the patients that I really worry that we will miss.
Dr de Virgilio. To answer your question, we did not
specifically look at whether there was a change in ejection
fraction in our study.
Second, as part of the study protocol, if a patient
developed a cardiac event after the event occurred, we
allowed the cardiologists, if they so desired, to “unblind”
the results of the study in case that would help them, but
in no instance did any of these nine patients subsequently
undergo an immediate cardiac revascularization.
So I do not really have the data to tell you whether
they had left main disease, but I think the important thing
of note is, again, the issue that five of the nine had a nor-
mal scan or a fixed defect. And, in fact, one of the cardiac
deaths had a very small reversible defect on the scan. In
talking to the cardiologists in a post hoc review, they
would never have intended to perform a coronary revas-
cularization or coronary angiography on this patient based
on that scan, and yet within 24 hours of the aortic surgery
the patient had a massive MI and expired.
Dr Joseph Rapp (San Francisco, Calf). At the risk of
preaching to the choir, all patients are at risk. The prob-
lem with these tests is that they do not do what they pro-
fess to do. They do not differentiate the risk in our
patients. I think there may be certain patients who do fall
out with a Persantine-thallium, but basically to apply that
test to all patients, I totally agree, is appropriate.
It is much more important, I believe, to exercise these
patients and see what happens to them when they are actu-
ally stressed rather than to do this chemical vasodilation of
the coronaries. In part that may be helpful, but you do not
get the idea from that test of coronary reserve, which is
really critical in these patients postoperatively.
Finally, I would like to ask a question and that is, in
our institution we are very careful about postoperative
tachycardia and feel that that is the single most dangerous
event for these patients after vascular surgery or any other
surgical procedure. Did you aggressively treat tachycardia,
and if you did, at what level and with what drugs?
Dr de Virgilio. I think that is a very good question, and
as you all know, as a result of the work again by the Oregon
group, it has been demonstrated that the use of beta block-
ade perioperatively does lower the adverse cardiac event rate.
That is certainly one of the potential weaknesses of the study.
We did, yes, aggressively attempt to treat tachycardia,
but there was not a set protocol for treatment of tachycar-
dia. The one thing I can counter to that is that there was
no significant difference in the adverse cardiac event rate
with respect to the use of beta blockade in this study.
Certainly a study where that is specifically included in the
protocol would be ideal.
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